VERICEL CORPORATION (VCEL) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 52.53M USD | Liabilities, Current |
| Cash and equivalents | 125.36M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 75.71M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 18.38M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $52.53M | $125.36M | (m) | $75.71M | $18.38M | (m) |
| 2026-03-31 | (m) | $47.16M | $109.30M | (m) | $72.38M | $18.35M | (m) |
| 2025-12-31 | (m) | $49.15M | $100.09M | (m) | $84.63M | $17.56M | (m) |
| 2025-09-30 | (m) | $45.58M | $100.40M | (m) | $60.43M | $18.16M | (m) |
| 2025-06-30 | (m) | $41.13M | $80.53M | (m) | $64.29M | $16.83M | (m) |
| 2025-03-31 | (m) | $39.45M | $73.49M | (m) | $52.90M | $17.11M | (m) |
| 2024-12-31 | (m) | $50.29M | $74.52M | (m) | $61.38M | $17.37M | (m) |
| 2024-09-30 | (m) | $41.35M | $53.68M | (m) | $48.48M | $15.76M | (m) |
| 2024-06-30 | (m) | $43.86M | $50.29M | (m) | $48.00M | $14.89M | (m) |
| 2024-03-31 | (m) | $36.47M | $62.94M | (m) | $49.93M | $13.56M | (m) |
| 2023-12-31 | (m) | $45.75M | $69.09M | (m) | $58.36M | $13.09M | (m) |
| 2023-09-30 | (m) | $35.95M | $60.47M | (m) | $39.73M | $12.62M | (m) |
| 2023-06-30 | (m) | $35.61M | $43.02M | (m) | $38.32M | $13.88M | (m) |
| 2023-03-31 | (m) | $28.75M | $61.83M | (m) | $38.36M | $15.37M | (m) |
| 2022-12-31 | (m) | $37.46M | $51.07M | (m) | $46.54M | $15.99M | (m) |
| 2022-09-30 | (m) | $27.00M | $65.22M | (m) | $34.30M | $16.73M | (m) |
| 2022-06-30 | (m) | $25.01M | $56.05M | (m) | $33.66M | $15.93M | (m) |
| 2022-03-31 | (m) | $21.73M | $55.66M | (m) | $31.86M | $14.38M | (m) |
| 2021-12-31 | (m) | $26.05M | $68.33M | (m) | $37.44M | $13.38M | (m) |
| 2021-09-30 | (m) | $18.83M | $54.55M | (m) | $28.91M | $13.06M | (m) |
| 2021-06-30 | (m) | $23.86M | $51.76M | (m) | $31.73M | $12.96M | (m) |
| 2021-03-31 | (m) | $23.23M | $58.15M | (m) | $29.12M | $10.32M | (m) |
| 2020-12-31 | (m) | $22.48M | $33.62M | (m) | $34.50M | $9.36M | (m) |
| 2020-09-30 | (m) | $21.31M | $43.51M | (m) | $26.17M | $10.08M | (m) |
| 2020-06-30 | (m) | $18.12M | $55.70M | (m) | $23.66M | $8.42M | (m) |
| 2020-03-31 | (m) | $18.13M | $45.62M | (m) | $24.17M | $7.28M | (m) |
| 2019-12-31 | (m) | $19.80M | $26.89M | (m) | $32.17M | $6.82M | (m) |
| 2019-09-30 | (m) | $15.11M | $36.91M | (m) | $19.96M | $6.82M | (m) |
| 2019-06-30 | (m) | $12.54M | $13.96M | (m) | $21.08M | $4.79M | (m) |
| 2019-03-31 | (m) | $12.94M | $35.08M | (m) | $18.77M | $4.06M | (m) |
| 2018-12-31 | (m) | $14.79M | (m) | (m) | $23.45M | $3.56M | (m) |
| 2018-09-30 | (m) | $14.99M | $53.29M | (m) | $15.53M | $3.64M | (m) |
| 2018-06-30 | (m) | $15.22M | $94.97M | (m) | $17.50M | $3.73M | (m) |
| 2018-03-31 | (m) | $13.88M | (m) | (m) | $13.16M | $3.90M | (m) |
| 2017-12-31 | (m) | $13.09M | (m) | (m) | $18.27M | $3.79M | (m) |
| 2017-09-30 | (m) | $14.53M | (m) | (m) | $15.43M | $4.05M | (m) |
| 2017-06-30 | (m) | $12.94M | (m) | (m) | $14.73M | $3.15M | (m) |
| 2017-03-31 | (m) | $14.75M | (m) | (m) | $12.13M | $3.96M | (m) |
| 2016-12-31 | (m) | $12.85M | (m) | (m) | $17.09M | $3.49M | (m) |
| 2016-09-30 | (m) | $15.36M | (m) | (m) | $7.87M | $3.61M | (m) |
| 2016-06-30 | (m) | $11.46M | (m) | (m) | $9.03M | $2.39M | (m) |
| 2016-03-31 | (m) | $13.77M | (m) | (m) | $9.67M | $1.94M | (m) |
| 2015-12-31 | (m) | $12.11M | (m) | (m) | $10.92M | $1.38M | (m) |
| 2015-09-30 | (m) | $9.26M | (m) | (m) | $7.64M | $1.64M | (m) |
| 2015-06-30 | (m) | $10.82M | (m) | (m) | $8.98M | $2.08M | (m) |
| 2015-03-31 | (m) | $12.62M | (m) | (m) | $9.17M | $2.00M | (m) |
| 2014-12-31 | (m) | $11.83M | (m) | (m) | $8.19M | $1.92M | (m) |
| 2014-09-30 | (m) | $12.48M | (m) | (m) | $3.96M | $1.71M | (m) |
| 2014-06-30 | (m) | $17.05M | (m) | (m) | $4.32M | $1.92M | (m) |
| 2014-03-31 | (m) | $6.11M | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $5.32M | $8.06M | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | $7.25M | $10.82M | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | $3.84M | $4.49M | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $4.28M | $9.23M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $5.66M | $13.64M | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | $6.98M | $21.09M | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | $11.99M | $28.67M | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | $22.35M | $36.73M | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $20.67M | $5.53M | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | $25.18M | $11.95M | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | $30.42M | $18.52M | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | $24.62M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $29.86M | $31.25M | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | $14.47M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $14.12M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $14.74M | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | $17.00M | (m) | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | $16.49M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |